Global Oncology Academy
The Global Oncology Academy (GOA) is an educational platform for physicians and other healthcare professionals involved in oncology. Its mission is to increase knowledge regarding the disease course of specific cancers and address key elements for successful management. The GOA series will also share the science around innovations in combination therapies, oncology strategies, and new developments.
For more information about GOA, visit www.globaloncologyacademy.org.
1-15 of 377
Assessing and Interpreting pCR in Perioperative NSCLC
Project Oncology®Assessing and Interpreting pCR in Perioperative NSCLC
Steve Jackson, PharmD
Alexander Spira, MD, PhD, FACP
Decoding epNECs: Diagnostic Challenges and Emerging Strategies
Project Oncology®Decoding epNECs: Diagnostic Challenges and Emerging Strategies
Brian P. McDonough, MD, FAAFP
Andrew E. Hendifar, MD
TROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
Oncology and HematologyTROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
Tiffany Traina, MD, FASCO
Advancing Management of Extrapulmonary NEC: The Emerging Role of DLL3
Project Oncology®Advancing Management of Extrapulmonary NEC: The Emerging Role of DLL3
Charles Turck, PharmD, BCPS, BCCCP
Rohit Thummalapalli, MD
Navigating Classification of High-Grade Neuroendocrine Neoplasms
Project Oncology®Navigating Classification of High-Grade Neuroendocrine Neoplasms
Charles Turck, PharmD, BCPS, BCCCP
Rohit Thummalapalli, MD
DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
Oncology and HematologyDESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
Sara A. Hurvitz, MD, FACP
- advertisement
Key Differences in Pulmonary and Extrapulmonary NEC Management
Project Oncology®Key Differences in Pulmonary and Extrapulmonary NEC Management
Alexandria May, PharmD, BCPS
Lowell B. Anthony, MD, FACP
Evolving epNEC Care: From Default Regimens to Precision-Driven Strategies
Project Oncology®Evolving epNEC Care: From Default Regimens to Precision-Driven Strategies
Alexandria May, PharmD, BCPS
Chandrikha Chandrasekharan, MBBS
Optimizing Treatment Intensity in Early-Stage TNBC
Project Oncology®Optimizing Treatment Intensity in Early-Stage TNBC
Roberto Leon-Ferre, MD
Matching TNBC Treatment Intensity to Patient Needs
Project Oncology®Matching TNBC Treatment Intensity to Patient Needs
Roberto Leon-Ferre, MD
DPYD Testing Before Fluoropyrimidine Therapy: Benefits, Risks, and Guidance
Project Oncology®DPYD Testing Before Fluoropyrimidine Therapy: Benefits, Risks, and Guidance
Daniel Hertz, PhD, PharmD
Breast Cancer Survivorship: Why Lifestyle Medicine Matters
Project Oncology®Breast Cancer Survivorship: Why Lifestyle Medicine Matters
Amy Comander, MD
- advertisement
Emerging TNBC Research: Biomarkers, Genomics, and Adaptive Treatment
Project Oncology®Emerging TNBC Research: Biomarkers, Genomics, and Adaptive Treatment
Roberto Leon-Ferre, MD
Implementing Lifestyle Medicine in Breast Cancer Survivorship Care
Project Oncology®Implementing Lifestyle Medicine in Breast Cancer Survivorship Care
Amy Comander, MD
Managing High-Risk Subgroups in Metastatic NSCLC
Project Oncology®Managing High-Risk Subgroups in Metastatic NSCLC
Charles Turck, PharmD, BCPS, BCCCP
Melina Marmarelis, MD
Deepa Rangachari, MD
